Paesmans M - Search Results

1

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.

Gancberg D, Järvinen T, di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J, Larsimont D. Gancberg D, et al. Among authors: paesmans m. Breast Cancer Res Treat. 2002 Jul;74(2):113-20. doi: 10.1023/a:1016146130767. Breast Cancer Res Treat. 2002. PMID: 12186371

2

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. Di Leo A, et al. Among authors: paesmans m. Clin Cancer Res. 2002 May;8(5):1107-16. Clin Cancer Res. 2002. PMID: 12006526 Clinical Trial.

3

3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.

Ferreira Filho AF, Crown J, Cardoso F, Nogaret JM, Duffy K, Dolci S, Rowan S, O'Higgins N, Batter V, Paesmans M, Piccart MJ, Di Leo A. Ferreira Filho AF, et al. Among authors: paesmans m. Anticancer Res. 2002 Jul-Aug;22(4):2471-6. Anticancer Res. 2002. PMID: 12174946 Clinical Trial.

4

HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.

Larsimont D, Di Leo A, Rouas G, Paesmans M, Ferreira-Filho F, Bernard C, Cardoso F, Verhest A, Piccart MJ, Gancberg D. Larsimont D, et al. Among authors: paesmans m. Anticancer Res. 2002 Jul-Aug;22(4):2485-90. Anticancer Res. 2002. PMID: 12174949

5

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.

Bernard-Marty C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A. Bernard-Marty C, et al. Among authors: paesmans m. Clin Breast Cancer. 2002 Dec;3(5):341-5. doi: 10.3816/CBC.2002.n.037. Clin Breast Cancer. 2002. PMID: 12533264

6

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D. Durbecq V, et al. Among authors: paesmans m. Mol Cancer Ther. 2004 Oct;3(10):1207-14. Mol Cancer Ther. 2004. PMID: 15486187 Clinical Trial.

7

Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.

Cardoso F, Paesmans M, Larsimont D, Durbecq V, Bernard-Marty C, Rouas G, Dolci S, Sotiriou C, Piccart MJ, Di Leo A. Cardoso F, et al. Among authors: paesmans m. Clin Breast Cancer. 2004 Dec;5(5):364-9. doi: 10.3816/cbc.2004.n.043. Clin Breast Cancer. 2004. PMID: 15585074

8

Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.

Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart MJ, Larsimont D. Ma Y, et al. Among authors: paesmans m. Clin Cancer Res. 2005 Jun 15;11(12):4393-9. doi: 10.1158/1078-0432.CCR-04-2256. Clin Cancer Res. 2005. PMID: 15958623

9

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.

Personeni N, Hendlisz A, Gallez J, Galdon MG, Larsimont D, Van Laethem JL, Nagy N, Barette M, Paesmans M, Cardoso F, Bleiberg H. Personeni N, et al. Among authors: paesmans m. Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62. doi: 10.1053/j.seminoncol.2005.04.029. Semin Oncol. 2005. PMID: 16399434

10

Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients.

Desmedt C, Ouriaghli FE, Durbecq V, Soree A, Colozza MA, Azambuja E, Paesmans M, Larsimont D, Buyse M, Harris A, Piccart M, Martiat P, Sotiriou C. Desmedt C, et al. Among authors: paesmans m. Int J Cancer. 2006 Dec 1;119(11):2539-45. doi: 10.1002/ijc.22149. Int J Cancer. 2006. PMID: 16929516

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

346 results

Search Page

Filters